<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01798836</url>
  </required_header>
  <id_info>
    <org_study_id>030675</org_study_id>
    <nct_id>NCT01798836</nct_id>
  </id_info>
  <brief_title>Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF</brief_title>
  <official_title>Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of oestradiol pre-treatment in a combined ultrashort flare GnRH
      agonist /GnRH antagonist protocol
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combined ultrashort flare GnRH agonist /GnRH antagonist protocol during COH cycle
      resulted in a significantly higher clinical pregnancy rate in patients with poor embryo
      quality, with repeated IVF failures and in poor responders. This is a protocol combining the
      effect of the microdose flare on endogenous FSH release with the benefit of an immediate LH
      suppression of the GnRH antagonist.

      A major disadvantage of the use of a GnRH antagonist protocol is the limitation for
      programming cycles, as the drugs administration is started on day 2 of the menstrual cycle
      and is strictly followed until the hCG criteria are met.

      The purpose of the study is to perform oestradiol pre-treatment with the combined ultrashort
      flare GnRH agonist /GnRH antagonist protocol aiming to

        1. better programme an antagonist cycle and

        2. improve the IVF outcome parameters, from the production of more follicles / oocytes up
           to the rise in live birth rates.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Obtained results were not good. Protocol was proved ineffective.
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Top embryo quality at day 2</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ectopic pregnancy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Positive Pregnancy Test</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Oestradiol and ultrashort GnRH agonist/antagonist protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women will begin pretreatment with 4 mg/day of 17 β-estradiol before the combination of GnRH ultashort agonist and antagonist protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRH agonist or antagonist protocol.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will undergo either a conventional short or long GnRH agonist or an antagonist protocol during COH for IVF</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oestradiol pre-treatment and combination of GnRH agonist/antagonist protocol</intervention_name>
    <arm_group_label>Oestradiol and ultrashort GnRH agonist/antagonist protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>GnRH agonist or antagonist protocol without oestradiol pre-treatment</intervention_name>
    <arm_group_label>GnRH agonist or antagonist protocol.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with poor or no response in previous COH for IVF cycles

          -  Patients with AMH &lt; 1 and/or FSH &gt;12

          -  Poor quality of embryos in previous cycles

          -  Age of patients up to 44 years

        Exclusion Criteria:

          -  Patients with normal ovarian reserve

          -  Patients with sonographically detected hydrosalpinges

          -  Presence of intramural fibroid distorting the endometrial cavity or submucous myoma or
             Asherman's syndrome

          -  Women with thrombofilia disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Salamalekis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National and Kapodistrian University of Athens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charalampos Siristatidis, Assistant Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National and Kapodistrian University of Athens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assisted Reproduction Unit, 3rd Department of Obstetrics and Gynecology. Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>12642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Griesinger G, Kolibianakis EM, Venetis C, Diedrich K, Tarlatzis B. Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis. Fertil Steril. 2010 Nov;94(6):2382-4. doi: 10.1016/j.fertnstert.2010.04.025. Epub 2010 May 26.</citation>
    <PMID>20537631</PMID>
  </reference>
  <reference>
    <citation>Bosch E. Can we skip weekends in GnRH antagonist cycles without compromising the final outcome? Fertil Steril. 2012 Jun;97(6):1299-300. doi: 10.1016/j.fertnstert.2012.04.024.</citation>
    <PMID>22656307</PMID>
  </reference>
  <results_reference>
    <citation>Orvieto R, Nahum R, Rabinson J, Gemer O, Anteby EY, Meltcer S. Ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist for patients with repeated IVF failures and poor embryo quality. Fertil Steril. 2009 Apr;91(4 Suppl):1398-400. doi: 10.1016/j.fertnstert.2008.04.064. Epub 2008 Aug 3.</citation>
    <PMID>18675974</PMID>
  </results_reference>
  <results_reference>
    <citation>Cédrin-Durnerin I, Guivarc'h-Levêque A, Hugues JN; Groupe d'Etude en Médecine et Endocrinologie de la Reproduction. Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized trial. Fertil Steril. 2012 Jun;97(6):1359-64.e1. doi: 10.1016/j.fertnstert.2012.02.028. Epub 2012 Mar 28.</citation>
    <PMID>22464760</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2013</study_first_submitted>
  <study_first_submitted_qc>February 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2013</study_first_posted>
  <last_update_submitted>August 4, 2015</last_update_submitted>
  <last_update_submitted_qc>August 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Siristatidis Charalampos, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor in Obstetrics and Gynecology/Assisted Reproduction</investigator_title>
  </responsible_party>
  <keyword>IVF/ICSI cycles, poor responders, ultrashort flare protocol, antagonist protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

